Results 61 to 70 of about 22,824 (81)

Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease

Genetics in Medicine, 2021
Daniel-G Bichet, Christiane Auray-Blais, Raphael Schiffmann   +2 more
exaly  

Gb3-Coated Bovine Milk Exosomes as a Practical Neutralizer for Shiga Toxin

ACS Applied Bio Materials, 2023
Zhifang Zhou, Haofei Hong, Jie Shi
exaly  

Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease

Molecular Genetics and Metabolism, 2017
Albina Nowak, Robert Desnick
exaly  

Effect of Gb3 in lipid rafts in resistance to Shiga-like toxin of mutant Vero cells

Microbial Pathogenesis, 2008
Kinnosuke Yahiro
exaly  

Verotoxin-1 Treatment or Manipulation of its Receptor Globotriaosylceramide (Gb3) for Reversal of Multidrug Resistance to Cancer Chemotherapy

Toxins, 2010
Kjell Grankvist
exaly  

Transmembrane BAX Inhibitor Motif Containing (TMBIM) Family Proteins Perturbs a trans-Golgi Network Enzyme, Gb3 Synthase, and Reduces Gb3 Biosynthesis

Journal of Biological Chemistry, 2010
Toshiyuki Yamaji, Kiyotaka Nishikawa, Kentaro Hanada   +2 more
exaly  

Peptides binding to a Gb3 mimic selected from a phage library

Biochimica Et Biophysica Acta - General Subjects, 2004
Yoshiko Miura, Masamichi Kamihira
exaly  

A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse

Pharmaceutics, 2018
Yuri Park, Dong-Kyu Jin, Young G Shin
exaly  

Tandem Mass Spectrometry Quantitation of Lyso‐Gb3 and Six Related Analogs in Plasma for Fabry Disease Patients

Current Protocols in Human Genetics, 2016
Michel Boutin, Christiane Auray-Blais
exaly